Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + telmisartan
- Development stage
- Unknown
- Lead developer
- EMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Egito is a fixed-dose combination (FDC) therapy developed by the Brazilian pharmaceutical company EMS for the treatment of patients with type 2 diabetes mellitus and hypertension. It combines two well-established pharmacological agents: empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and telmisartan, an angiotensin II receptor blocker (ARB). Empagliflozin works by reducing renal glucose reabsorption in the proximal tubules, leading to increased urinary glucose excretion and lower blood glucose levels. Telmisartan acts by selectively blocking the binding of angiotensin II to the AT1 receptor, which results in vasodilation and a reduction in blood pressure. This combination is intended to simplify treatment regimens and improve clinical outcomes in patients who require management of both metabolic and cardiovascular risk factors.
- Brand names
- Egito
- Other names
- empagliflozin + telmisartan
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A1 (Sodium Glucose Cotransporter 1)PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on empagliflozin + telmisartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + telmisartan.